Base de dados : MEDLINE
Pesquisa : D02.033.100.400 [Categoria DeCS]
Referências encontradas : 93 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10 ir para página                        

  1 / 93 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22267580
[Au] Autor:Liu JJ; Horst R; Katritch V; Stevens RC; Wüthrich K
[Ad] Endereço:Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
[Ti] Título:Biased signaling pathways in ß2-adrenergic receptor characterized by 19F-NMR.
[So] Source:Science;335(6072):1106-10, 2012 Mar 02.
[Is] ISSN:1095-9203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extracellular ligand binding to G protein-coupled receptors (GPCRs) modulates G protein and ß-arrestin signaling by changing the conformational states of the cytoplasmic region of the receptor. Using site-specific (19)F-NMR (fluorine-19 nuclear magnetic resonance) labels in the ß(2)-adrenergic receptor (ß(2)AR) in complexes with various ligands, we observed that the cytoplasmic ends of helices VI and VII adopt two major conformational states. Changes in the NMR signals reveal that agonist binding primarily shifts the equilibrium toward the G protein-specific active state of helix VI. In contrast, ß-arrestin-biased ligands predominantly impact the conformational states of helix VII. The selective effects of different ligands on the conformational equilibria involving helices VI and VII provide insights into the long-range structural plasticity of ß(2)AR in partial and biased agonist signaling.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/metabolismo
Receptores Adrenérgicos beta 2/química
Receptores Adrenérgicos beta 2/metabolismo
Transdução de Sinais
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos beta 2/química
Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Arrestinas/metabolismo
Sítios de Ligação
Carbazóis/química
Carbazóis/metabolismo
Carbazóis/farmacologia
Citoplasma/química
Agonismo Parcial de Drogas
Flúor
Isoetarina/química
Isoetarina/metabolismo
Isoetarina/farmacologia
Isoproterenol/metabolismo
Ligantes
Modelos Moleculares
Ressonância Magnética Nuclear Biomolecular
Propanolaminas/química
Propanolaminas/metabolismo
Propanolaminas/farmacologia
Conformação Proteica
Estrutura Secundária de Proteína
Relação Estrutura-Atividade
beta-Arrestinas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Arrestins); 0 (Carbazoles); 0 (Ligands); 0 (Propanolamines); 0 (Receptors, Adrenergic, beta-2); 0 (beta-Arrestins); 0K47UL67F2 (carvedilol); 284SYP0193 (Fluorine); L628TT009W (Isoproterenol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:1203
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120124
[St] Status:MEDLINE
[do] DOI:10.1126/science.1215802


  2 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9451638
[Au] Autor:Carvalho P; Johnson SR; Charan NB
[Ad] Endereço:Pulmonary Research Laboratory, Department of Veterans Affairs Medical Center, Boise, Idaho 83702, USA.
[Ti] Título:Non-cAMP-mediated bronchial arterial vasodilation in response to inhaled beta-agonists.
[So] Source:J Appl Physiol (1985);84(1):215-21, 1998 Jan.
[Is] ISSN:8750-7587
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We studied the dose-dependent effects of inhaled isoetharine HCl, a beta-adrenergic bronchodilator (2.5, 5.0, 10.0, and 20.0 mg), on bronchial blood flow (Qbr) in anesthetized sheep. Isoetharine resulted in a dose-dependent increase in Qbr. With a total dose of 17.5 mg, Qbr increased from baseline values of 22 +/- 3.4 (SE) to 60 +/- 16 ml/min (P < 0.001), an effect independent of changes in cardiac output and systemic arterial pressure. To further study whether synthesis of endogenous nitric oxide (NO) affects beta-agonist-induced increases in Qbr, we administered isoetharine (20 mg) by inhalation before and after the NO-synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME). Intravenous L-NAME (30 mg/kg) rapidly decreased Qbr by approximately 80% of baseline, whereas L-NAME via inhalation (10 mg/kg) resulted in a delayed and smaller (approximately 22%) decrease. Pretreatment with L-NAME via both routes of administration attenuated bronchial arterial vasodilation after subsequent challenge with isoetharine. We conclude that isoetharine via inhalation increases Qbr in a dose-dependent manner and that beta-agonist-induced relaxation of vascular smooth muscle in the bronchial vasculature is partially mediated via synthesis of NO.
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/farmacologia
Artérias Brônquicas/efeitos dos fármacos
AMP Cíclico/fisiologia
Vasodilatação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração por Inalação
Agonistas alfa-Adrenérgicos/farmacologia
Agonistas Adrenérgicos beta/administração & dosagem
Animais
Relação Dose-Resposta a Droga
Inibidores Enzimáticos/administração & dosagem
Inibidores Enzimáticos/farmacologia
Hemodinâmica/efeitos dos fármacos
Injeções Intravenosas
Isoetarina/administração & dosagem
Isoetarina/farmacologia
NG-Nitroarginina Metil Éster/administração & dosagem
NG-Nitroarginina Metil Éster/farmacologia
Óxido Nítrico Sintase/antagonistas & inibidores
Consumo de Oxigênio/efeitos dos fármacos
Fenilefrina/farmacologia
Ovinos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Adrenergic alpha-Agonists); 0 (Adrenergic beta-Agonists); 0 (Enzyme Inhibitors); 1WS297W6MV (Phenylephrine); E0399OZS9N (Cyclic AMP); EC 1.14.13.39 (Nitric Oxide Synthase); V55S2QJN2X (NG-Nitroarginine Methyl Ester); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9803
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980206
[St] Status:MEDLINE


  3 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9209213
[Au] Autor:Finkelstein F
[Ti] Título:Isoetherine or albuterol for acute asthma.
[So] Source:Am J Med;102(1):130, 1997 Jan.
[Is] ISSN:0002-9343
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Albuterol/farmacocinética
Asma/tratamento farmacológico
Broncodilatadores/farmacocinética
Isoetarina/farmacocinética
[Mh] Termos MeSH secundário: Doença Aguda
Albuterol/administração & dosagem
Broncodilatadores/administração & dosagem
Seres Humanos
Isoetarina/administração & dosagem
Equivalência Terapêutica
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Bronchodilator Agents); QF8SVZ843E (Albuterol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9707
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:970101
[St] Status:MEDLINE


  4 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9049753
[Au] Autor:Charan NB; Johnson SR; Lakshminarayan S; Thompson WH; Carvalho P
[Ad] Endereço:Pulmonary Research Laboratory, Veterans Affairs Medical Center, Boise, Idaho 83702, USA. ncharan@micron.net
[Ti] Título:Nitric oxide and beta-adrenergic agonist-induced bronchial arterial vasodilation.
[So] Source:J Appl Physiol (1985);82(2):686-92, 1997 Feb.
[Is] ISSN:8750-7587
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In anesthetized sheep, we measured bronchial blood flow (Qbr) by an ultrasonic flow probe to investigate the interaction between inhaled nitric oxide (NO; 100 parts/million) given for 5 min and 5 ml of aerosolized isoetharine (1.49 x 10(-2) M concentration). NO and isoetharine increased Qbr from 26.5 +/- 6.5 to 39.1 (SE) +/- 10.6 and 39.7 +/- 10.7 ml/min, respectively (n = 5). Administration of NO immediately after isoetharine further increased Qbr to 57.3 +/- 15.1 ml/min. NO synthase inhibitor N(omega)-nitro-L-arginine methyl ester hydrochloride (L-NAME; 30 mg/kg, in 20 ml saline given i.v.) decreased Qbr to 14.6 +/- 2.6 ml/min. NO given three times alternately with isoetharine progressively increased Qbr from 14.6 +/- 2.6 to 74.3 +/- 17.0 ml/min, suggesting that NO and isoetharine potentiate vasodilator effects of each other. In three other sheep, after L-NAME three sequential doses of isoetharine increased Qbr from 10.2 +/- 3.4 to 11.5 +/- 5.7, 11.7 +/- 4.7, and 13.3 +/- 5.7 ml/min, respectively, indicating that effects of isoetharine are predominantly mediated through synthesis of NO. When this was followed by three sequential administrations of NO, Qbr increased by 146, 172, and 185%, respectively. Thus in the bronchial circulation, there seems to be a close interaction between adenosine 3',5'-cyclic monophosphate- and guanosine 3',5'-cyclic monophosphate-mediated vasodilation.
[Mh] Termos MeSH primário: Artérias Brônquicas/efeitos dos fármacos
Isoetarina/farmacologia
Óxido Nítrico/farmacologia
Vasodilatação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Ovinos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
31C4KY9ESH (Nitric Oxide); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9706
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:970201
[St] Status:MEDLINE


  5 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8629678
[Au] Autor:Shrestha M; Gourlay S; Robertson S; Bidadi K; Wainscott M; Hayes J
[Ad] Endereço:Division of Emergency Medicine, Department of Surgery, University of Texas Southwestern Medical School, Dallas, USA.
[Ti] Título:Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects.
[So] Source:Am J Med;100(3):323-7, 1996 Mar.
[Is] ISSN:0002-9343
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare the magnitudes of the immediate effects of the nebulized beta-agonists isoetharine and albuterol in the treatment of acute severe asthma. PATIENTS AND METHODS: Fifty-one adults presenting with severe asthma exacerbations (forced expiratory volumes in the first second of exhalation [FEV1] <40% of predicted) to the emergency department were randomized (double-blind) to receive hourly inhaled nebulization treatment with either isoetharine (5 mg) or albuterol (2.5 mg). The FEV1 was measured immediately before and after each nebulized treatment. Any side effects were recorded. RESULTS: Immediately after the first nebulized treatment, the isoetharine group improved its mean FEV1 (+/-SEM) by a significantly greater amount than did the albuterol group: 60% +/- 11% versus 39% +/- 5%, respectively (P <0.05). One hour later the mean FEV1 were equivalent. This pattern repeated itself after the second hourly treatment. The two groups did not differ in any outcome parameters (FEV1 at discharge, number of nebulized treatments required, the number of inpatient admissions, number of clinical relapses after discharge). More patients treated with isoetharine had side effects (36% versus 4% for albuterol, P <0.01), 1 of whom required discontinuation from the study. CONCLUSIONS: Both medications were equally effective in alleviating bronchospasm. The immediate effect of isoetharine was significantly greater, but equalized that of albuterol within an hour after treatment. There were more side effects with isoetharine.
[Mh] Termos MeSH primário: Albuterol/uso terapêutico
Asma/tratamento farmacológico
Broncodilatadores/uso terapêutico
Volume Expiratório Forçado/efeitos dos fármacos
Isoetarina/uso terapêutico
[Mh] Termos MeSH secundário: Doença Aguda
Administração por Inalação
Adulto
Albuterol/administração & dosagem
Albuterol/efeitos adversos
Asma/fisiopatologia
Broncodilatadores/administração & dosagem
Broncodilatadores/efeitos adversos
Método Duplo-Cego
Esquema de Medicação
Feminino
Seres Humanos
Isoetarina/administração & dosagem
Isoetarina/efeitos adversos
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Bronchodilator Agents); QF8SVZ843E (Albuterol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9606
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:960301
[St] Status:MEDLINE


  6 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7741336
[Au] Autor:Gomez HF; Moore L; McKinney P; Phillips S; Guven H; Brent J
[Ad] Endereço:Rocky Mountain Poison and Drug Center, Denver General Hospital, University of Colorado, Health Sciences Center, USA.
[Ti] Título:Elevation of breath ethanol measurements by metered-dose inhalers.
[So] Source:Ann Emerg Med;25(5):608-11, 1995 May.
[Is] ISSN:0196-0644
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:STUDY OBJECTIVE: Metered-dose inhalers (MDIs) may contain as much as 38% ethanol. We evaluated the effects of ethanol-containing MDIs on breath alcohol testing. DESIGN: Prospective, single-blind, crossover, controlled study. PARTICIPANTS: Three healthy male volunteers 29 to 36 years old. INTERVENTION: We studied three brands: Tornalate, (38% ethanol), Bronkometer, (30% ethanol), and Alupent, (0% ethanol). The effects of each MDI on breath and blood ethanol measurements were evaluated separately. Two puffs of each brand of MDI were administered. Breath ethanol measurements were obtained at baseline and .25, .5, 1, 2, 3, 5, and 10 minutes after MDI use. Blood ethanol measurements were obtained at baseline and 1 and 10 minutes after MDI use. RESULTS: Overall, Tornalate had the highest breath ethanol readings, with a mean ethanol level of 189 mg/dL recorded just after MDI use. Breath ethanol levels subsequently decreased rapidly over time. Mean breath ethanol concentrations were lower after the use of Bronkometer and undetectable after the use of Alupent. Blood ethanol levels were undetectable at all times tested. CONCLUSION: MDIs may cause elevations of breath alcohol above the legal criteria for intoxication. These effects are transient and may be prevented by a 10-minute interval between the use of an MDI and breath alcohol testing.
[Mh] Termos MeSH primário: Testes Respiratórios/métodos
Broncodilatadores/administração & dosagem
Etanol/análise
[Mh] Termos MeSH secundário: Administração por Inalação
Adulto
Estudos Cross-Over
Etanol/sangue
Etanolaminas/administração & dosagem
Seres Humanos
Isoetarina/administração & dosagem
Masculino
Metaproterenol/administração & dosagem
Nebulizadores e Vaporizadores
Estudos Prospectivos
Valores de Referência
Método Simples-Cego
Fatores de Tempo
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Ethanolamines); 3K9958V90M (Ethanol); 53QOG569E0 (Metaproterenol); 9KY0QXD6LI (bitolterol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9506
[Cu] Atualização por classe:160419
[Lr] Data última revisão:
160419
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:950501
[St] Status:MEDLINE


  7 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7712766
[Au] Autor:Koumbourlis AC; Mutich RL; Motoyama EK
[Ad] Endereço:Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh, School of Medicine, PA, USA.
[Ti] Título:Contribution of airway hyperresponsiveness to lower airway obstruction after extracorporeal membrane oxygenation for meconium aspiration syndrome.
[So] Source:Crit Care Med;23(4):749-54, 1995 Apr.
[Is] ISSN:0090-3493
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine whether airway hyperresponsiveness contributes to the development of lower airway obstruction in infants recovering from severe meconium aspiration syndrome treated with extracorporeal membrane oxygenation (ECMO). DESIGN: Prospective comparison study of the response to bronchodilator during the acute and convalescent phase of severe meconium aspiration. SETTING: Pediatric/neonatal intensive care unit in a tertiary care hospital. PATIENTS: Seven neonates with severe meconium aspiration syndrome that was refractory to conventional mechanical ventilation, requiring ECMO treatment. INTERVENTIONS: Evaluation of the effect of bronchodilator treatment on the airway function at a postnatal age of 14 +/- 2.7 (SEM) days, after the patients had been off ECMO for 4.6 +/- 1.4 days, and comparison with the response the same patients had shown at a postnatal age of 2.7 +/- 0.6 days, when they had been on ECMO for 1.3 +/- 0.6 days. Lung mechanics and lower airway function were measured and compared before and after administration of aerosolized isoetharine early in the course of ECMO and again several days after ECMO. Maximum expiratory flow-volume curves produced by the deflation flow-volume curve technique were used for evaluating the lower airway function, and partial passive flow-volume curves were used for measuring respiratory system compliance and resistance. MEASUREMENTS AND MAIN RESULTS: During the first test, isoetharine produced a mild increase in maximum expiratory flows at 25% (MEF25) of forced vital capacity (FVC) (48 +/- 27% compared with baseline values), without significant change in the MEF25 to FVC ratio. During the second test approximately 2 wks later (post-ECMO), isoetharine increased MEF25 by 123 +/- 29% and increased the MEF25/FVC by 40 +/- 13% compared with baseline values. The percent change in both indices was significantly higher during the second test (p < .05) than in the first test. CONCLUSIONS: Airway obstruction in infants recovering from severe meconium aspiration syndrome is partially reversible with aerosolized isoetharine, indicating that airway hyperresponsiveness contributes to the pathogenesis of airway obstruction.
[Mh] Termos MeSH primário: Obstrução das Vias Respiratórias/fisiopatologia
Hiper-Reatividade Brônquica
Oxigenação por Membrana Extracorpórea
Síndrome de Aspiração de Mecônio/fisiopatologia
[Mh] Termos MeSH secundário: Obstrução das Vias Respiratórias/etiologia
Resistência das Vias Respiratórias
Seres Humanos
Recém-Nascido
Isoetarina/uso terapêutico
Complacência Pulmonar
Fluxo Expiratório Máximo
Síndrome de Aspiração de Mecônio/complicações
Síndrome de Aspiração de Mecônio/terapia
Estudos Prospectivos
Capacidade Vital
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9505
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:950401
[St] Status:MEDLINE


  8 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1555473
[Au] Autor:van Lunteren E; Coreno A
[Ad] Endereço:Department of Medicine, University Hospitals of Cleveland.
[Ti] Título:Inhaled albuterol powder for pulmonary function testing.
[So] Source:Chest;101(4):985-8, 1992 Apr.
[Is] ISSN:0012-3692
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To assess the role of albuterol powder in testing for reversibility of airflow obstruction during routine pulmonary function testing, spirometric data from subjects with baseline FEV1/FVC less than 70 percent and FEV1 less than 80 percent predicted who received inhaled albuterol powder (n = 42) were compared with those who received isoetharine aerosol via metered dose inhaler (n = 49). Prebronchodilator lung function was comparable for the albuterol and isoetharine groups. With albuterol powder, 14 (33 percent) of 42 subjects showed reversibility of airflow obstruction (defined as a 15 percent or greater improvement in either FEV1 or FVC) as compared with 30 (61 percent) of 49 subjects with isoetharine aerosol. The significantly (p less than 0.01) lower rate of improvement with albuterol powder was especially prominent in subjects with moderate airflow obstruction (FEV1/FVC of 45 to 59 percent). These data do not support the substitution of inhaled albuterol powder for isoetharine aerosol in assessing for reversibility of airflow obstruction during routine pulmonary function testing.
[Mh] Termos MeSH primário: Albuterol
Testes de Função Respiratória/métodos
[Mh] Termos MeSH secundário: Aerossóis
Albuterol/administração & dosagem
Volume Expiratório Forçado/efeitos dos fármacos
Seres Humanos
Isoetarina/administração & dosagem
Pós
Capacidade Vital/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Powders); QF8SVZ843E (Albuterol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9205
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:920401
[St] Status:MEDLINE


  9 / 93 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1386420
[Au] Autor:Nakayama DK; Mutich R; Motoyama EK
[Ad] Endereço:Department of Pediatric Surgery, Children's Hospital of Pittsburgh, PA 15213-3417.
[Ti] Título:Pulmonary dysfunction after primary closure of an abdominal wall defect and its improvement with bronchodilators.
[So] Source:Pediatr Pulmonol;12(3):174-80, 1992 Mar.
[Is] ISSN:8755-6863
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To determine the extent of pulmonary dysfunction following primary closure of an abdominal wall defect, we obtained pulmonary function tests (PFT) in 11 newborn infants with gastroschisis and 6 with large omphaloceles admitted to a newborn ICU in a children's hospital. Patients were 1 to 30 days of age at the time of the PFT; all required endotracheal intubation and mechanical ventilation for operative procedures or for postoperative ventilatory support. Full-term infants (n = 21) undergoing minor surgical procedures provided comparative measurements. Flow-volume curves were obtained with manual inflation of the lungs followed by forced deflation using negative pressure, or by passive expiration, under sedation and pharmacologic paralysis. Deflation flow-volume curves gave measurements of forced vital capacity (FVC) and maximal expiratory flow at 25% of vital capacity from residual volume (MEF25). Modified passive mechanics technique gave passive expiratory curves that provided measurements of respiratory system compliance (Crs) and resistance (Rrs). Tests were done: within 48 h (period A), 3-7 days (period B), and 8-30 days after surgical repair (period C). Pulmonary function testing after nebulized 0.1% isoetharine (a bronchodilator), to test for bronchial reactivity, began midway during the study period in 15 patients. Preoperative and postoperative tests were obtained in 5 patients. Closure of an abdominal wall defect decreased FVC, Crs, and MEF25 by up to 50% of normal, reference values after surgery (P less than 0.05). FVC and MEF25 approached values of normal infants by 4 weeks, whereas Crs remained 50% lower.(ABSTRACT TRUNCATED AT 250 WORDS)
[Mh] Termos MeSH primário: Músculos Abdominais/anormalidades
Hérnia Umbilical/cirurgia
Isoetarina/uso terapêutico
Pneumopatias/tratamento farmacológico
Complicações Pós-Operatórias/tratamento farmacológico
[Mh] Termos MeSH secundário: Músculos Abdominais/cirurgia
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Isoetarina/farmacologia
Pneumopatias/epidemiologia
Complicações Pós-Operatórias/epidemiologia
Mecânica Respiratória/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9209
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920301
[St] Status:MEDLINE


  10 / 93 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:1928879
[Au] Autor:Emerman CL; Cydulka RK; Effron D; Lukens TW; Gershman H; Boehm SP
[Ad] Endereço:Department of Emergency Medicine, MetroHealth Medical Center, Cleveland, Ohio 44109.
[Ti] Título:A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma.
[So] Source:Ann Emerg Med;20(10):1090-3, 1991 Oct.
[Is] ISSN:0196-0644
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:STUDY OBJECTIVE: To determine whether treatment of acute asthma with repeated doses of nebulized albuterol leads to greater bronchodilation and lower hospital admission rate than treatment with nebulized isoetharine. DESIGN: Randomized, double-blinded, controlled trial of albuterol and isoetharine. TYPE OF PARTICIPANTS: Patients between 18 and 50 years old presenting with acute asthma. Patients were excluded if they had a history of sensitivity to the study drugs, had congestive heart failure or chronic-obstructive pulmonary disease, or were unable to perform spirometry. One hundred three patients were entered into the study. INTERVENTIONS: All patients received oxygen and methylprednisolone in addition to administration of either isoetharine or albuterol. The nebulized aerosol was given at hourly intervals for a total of three doses. MEASUREMENTS AND MAIN RESULTS: Spirometry was performed before treatment and again at 90 and 180 minutes. Initial forced expiratory volume at one minute (FEV1) was 38.1% of predicted normal for the albuterol group and 36.0% of predicted normal for the isoetharine group. At 180 minutes, FEV1 was 55.6% of predicted normal for the albuterol group and 57.1% of predicted for the isoetharine group (NS). Twenty-eight percent of the albuterol group required admission compared with 26% of the isoetharine group (NS). There was no difference in occurrence of side effects between the two groups. CONCLUSION: Repeated doses of albuterol do not lead to a greater improvement in pulmonary function or a lower hospital admission rate than treatment with isoetharine.
[Mh] Termos MeSH primário: Albuterol/uso terapêutico
Asma/tratamento farmacológico
Isoetarina/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Albuterol/efeitos adversos
Feminino
Volume Expiratório Forçado
Seres Humanos
Isoetarina/efeitos adversos
Masculino
Meia-Idade
Nebulizadores e Vaporizadores
Espirometria
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
QF8SVZ843E (Albuterol); YV0SN3276Q (Isoetharine)
[Em] Mês de entrada:9111
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:911001
[St] Status:MEDLINE



página 1 de 10 ir para página                        
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde